Enzo Biochem (ENZ) 10-Q13 Jun 242024 Q3 Quarterly reportFinancial data

Company Profile

Cover

Cover - shares	9 Months Ended
Cover - shares	Apr. 30, 2024	Jun. 10, 2024
Document Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Transition Report	false
Entity Interactive Data Current	Yes
Amendment Flag	false
Document Period End Date	Apr. 30, 2024
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q3
Entity Information [Line Items]
Entity Registrant Name	ENZO BIOCHEM, INC
Entity Central Index Key	0000316253
Entity File Number	001-09974
Entity Tax Identification Number	13-2866202
Entity Incorporation, State or Country Code	NY
Current Fiscal Year End Date	--07-31
Entity Current Reporting Status	Yes
Entity Shell Company	false
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Contact Personnel [Line Items]
Entity Address, Address Line One	21 Executive Blvd
Entity Address, Address Line Two	Farmingdale
Entity Address, City or Town	New York
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	11735
Entity Phone Fax Numbers [Line Items]
City Area Code	(631)
Local Phone Number	755-5500
Entity Listings [Line Items]
Title of 12(b) Security	Common stock $0.01 par value
Trading Symbol	ENZ
Security Exchange Name	NYSE
Entity Common Stock, Shares Outstanding		51,457,660

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Apr. 30, 2024	Jul. 31, 2023
Current assets:
Cash and cash equivalents	$ 57,156	$ 82,373
Accounts receivable, net	3,935	4,808
Inventories, net	7,324	7,939
Prepaid expenses and other current assets, including $5,000 escrow at April 30, 2024 and $1,000 restricted cash at July 31, 2023	7,321	3,336
Total current assets	75,736	98,456
Property, plant, and equipment, net	12,638	13,086
Right-of-use assets	2,959	3,626
Other assets, including $5,000 escrow at July 31, 2023	591	5,745
Non-current assets of discontinued operations, net	1,545	967
Total assets	93,469	121,880
Current liabilities:
Accounts payable – trade	1,520	3,575
Accrued liabilities	5,376	11,743
Current portion of operating lease liabilities	799	980
Current portion of long term debt	75	75
Convertible debentures	3,609	2,514
Current liabilities of discontinued operations, net	10,284	21,102
Total current liabilities	21,663	39,989
Operating lease liabilities, non-current	2,595	3,160
Long term debt, net	180	269
Total liabilities	24,438	43,418
Contingencies – see Note 13
Stockholders’ equity:
Preferred Stock, $.01 par value; authorized 25,000,000 shares; no shares issued or outstanding
Common Stock, $.01 par value; authorized 75,000,000 shares; shares issued and outstanding: 51,227,535 at April 30, 2024 and 49,997,631 at July 31, 2023	511	499
Additional paid-in capital	347,069	344,435
Accumulated deficit	(281,047)	(268,350)
Accumulated other comprehensive income	2,498	1,878
Total stockholders’ equity	69,031	78,462
Total liabilities and stockholders’ equity	$ 93,469	$ 121,880

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - USD ($) $ in Thousands	Apr. 30, 2024	Jul. 31, 2023
Statement of Financial Position [Abstract]
Other, including restricted cash (in Dollars)	$ 5,000	$ 1,000
Other assets, including escrow (in Dollars)		$ 5,000
Preferred stock par value (in Dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized	25,000,000	25,000,000
Preferred Stock, shares issued
Preferred Stock, shares outstanding
Common stock, par value (in Dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	75,000,000	75,000,000
Common stock, shares issued	51,227,535	49,997,631
Common stock, shares outstanding	51,227,535	49,997,631

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Apr. 30, 2024	Apr. 30, 2023	Apr. 30, 2024	Apr. 30, 2023
Income Statement [Abstract]
Revenues	$ 8,022	$ 7,485	$ 24,381	$ 22,102
Operating costs and expenses:
Cost of revenues	4,289	4,476	12,969	13,681
Research and development	605	884	2,035	2,708
Selling, general and administrative	4,479	6,212	16,550	17,078
Legal and related expense, net	692	4,265	2,527	6,160
Total operating costs and expenses	10,065	15,837	34,081	39,627
Operating loss	(2,043)	(8,352)	(9,700)	(17,525)
Other income (expense):
Interest, net	726	(36)	2,595	99
Change in fair value of convertible debentures	(384)		(1,095)
Other	94	144	373	262
Foreign exchange (loss) gain	(524)	347	(842)	1,022
Total other income (expense)	(88)	455	1,031	1,383
Loss before income taxes	(2,131)	(7,897)	(8,669)	(16,142)
Income taxes
Net loss from continuing operations	(2,131)	(7,897)	(8,669)	(16,142)
Net loss from discontinued operations	(889)	(7,290)	(4,028)	(21,000)
Net loss	$ (3,020)	$ (15,187)	$ (12,697)	$ (37,142)
Net loss per common share – basic and diluted:
Continuing operations (in Dollars per share)	$ (0.04)	$ (0.16)	$ (0.17)	$ (0.33)
Discontinued operations (in Dollars per share)	(0.02)	(0.15)	(0.08)	(0.43)
Total net loss per basic and diluted common share (in Dollars per share)	$ (0.06)	$ (0.31)	$ (0.25)	$ (0.76)
Weighted average common shares outstanding:
Basic (in Shares)	51,214	49,384	50,629	48,944

Consolidated Statements of Op_2

Consolidated Statements of Operations (Unaudited) (Parentheticals) - $ / shares	3 Months Ended		9 Months Ended
	Apr. 30, 2024	Apr. 30, 2023	Apr. 30, 2024	Apr. 30, 2023
Income Statement [Abstract]
Continuing operations, diluted	$ (0.04)	$ (0.16)	$ (0.17)	$ (0.33)
Discontinued operations, diluted	(0.02)	(0.15)	(0.08)	(0.43)
Total net income (loss) per diluted common share (in Dollars per share)	$ (0.06)	$ (0.31)	$ (0.25)	$ (0.76)
Diluted (in Shares)	51,214	49,384	50,629	48,944

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Apr. 30, 2024	Apr. 30, 2023	Apr. 30, 2024	Apr. 30, 2023
Statement of Comprehensive Income [Abstract]
Net loss	$ (3,020)	$ (15,187)	$ (12,697)	$ (37,142)
Other comprehensive (loss) income:
Foreign currency translation adjustments	452	(372)	620	(994)
Comprehensive loss	$ (2,568)	$ (15,559)	$ (12,077)	$ (38,136)

Consolidated Statements of Stoc

Consolidated Statements of Stockholders’ Equity (Unaudited) - USD ($) $ in Thousands	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Income	Total
Balance at Jul. 31, 2022	$ 487	$ 339,462	$ (288,638)	$ 3,151	$ 54,462
Balance (in Shares) at Jul. 31, 2022	48,720,454
Net loss			(37,142)		(37,142)
Share-based compensation charges		1,508			1,508
Vesting of restricted stock units	$ 1				1
Vesting of restricted stock units (in Shares)	86,667
Vesting of performance stock units
Vesting of performance stock units (in Shares)	12,600
Exercise of stock options		14			14
Exercise of stock options (in Shares)	6,667
Issuance of common stock for employee 401(k) plan match	$ 8	1,071			1,079
Issuance of common stock for employee 401(k) plan match (in Shares)	843,100
Foreign currency translation adjustments				(994)	(994)
Balance at Apr. 30, 2023	$ 496	342,055	(325,780)	2,157	18,928
Balance (in Shares) at Apr. 30, 2023	49,669,488
Balance at Jan. 31, 2023	$ 487	340,407	(310,593)	2,529	32,830
Balance (in Shares) at Jan. 31, 2023	48,733,054
Net loss			(15,187)		(15,187)
Share-based compensation charges		563			563
Vesting of restricted stock units	$ 1				1
Vesting of restricted stock units (in Shares)	86,667
Exercise of stock options		14			14
Exercise of stock options (in Shares)	6,667
Issuance of common stock for employee 401(k) plan match	$ 8	1,071			1,079
Issuance of common stock for employee 401(k) plan match (in Shares)	843,100
Foreign currency translation adjustments				(372)	(372)
Balance at Apr. 30, 2023	$ 496	342,055	(325,780)	2,157	18,928
Balance (in Shares) at Apr. 30, 2023	49,669,488
Balance at Jul. 31, 2023	$ 499	344,435	(268,350)	1,878	78,462
Balance (in Shares) at Jul. 31, 2023	49,997,631
Net loss			(12,697)		(12,697)
Share-based compensation charges		1,543			$ 1,543
Exercise of stock options (in Shares)
Vested restricted and performance stock units issued	$ 4				$ 4
Vested restricted and performance stock units issued (in Shares)	394,442
Common stock issued for Asset Purchase Agreement bonus payment	$ 3	481			484
Common stock issued for Asset Purchase Agreement bonus payment (in Shares)	347,610
Issuance of common stock for employee 401(k) plan match	$ 5	610			615
Issuance of common stock for employee 401(k) plan match (in Shares)	487,852
Foreign currency translation adjustments				620	620
Balance at Apr. 30, 2024	$ 511	347,069	(281,047)	2,498	69,031
Balance (in Shares) at Apr. 30, 2024	51,227,535
Balance at Jan. 31, 2024	$ 504	346,252	(278,027)	2,046	70,775
Balance (in Shares) at Jan. 31, 2024	50,489,771
Net loss			(3,020)		(3,020)
Share-based compensation charges		207			207
Vested restricted and performance stock units issued	$ 2				2
Vested restricted and performance stock units issued (in Shares)	249,912
Issuance of common stock for employee 401(k) plan match	$ 5	610			615
Issuance of common stock for employee 401(k) plan match (in Shares)	487,852
Foreign currency translation adjustments				452	452
Balance at Apr. 30, 2024	$ 511	$ 347,069	$ (281,047)	$ 2,498	$ 69,031
Balance (in Shares) at Apr. 30, 2024	51,227,535

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Apr. 30, 2024	Apr. 30, 2023
Cash flows from operating activities:
Net loss	$ (12,697)	$ (37,142)
Adjustments to reconcile net loss to net cash used in operating activities:
Change in fair value of convertible debentures	1,095
Depreciation and amortization of property, plant and equipment	874	2,076
Share-based compensation charges	1,543	1,508
Share-based 401(k) employer match expense	494	772
Unrealized foreign exchange loss (gain)	764	(1,081)
Gain on operating lease terminations	(554)
Changes in operating assets and liabilities:
Accounts receivable	2,475	1,861
Inventories	636	91
Prepaid expenses and other assets	(88)	1,350
Accounts payable – trade	(7,654)	5,128
Accrued liabilities, other current liabilities and other liabilities	(12,062)	5,492
Total adjustments	(12,477)	17,197
Net cash used in operating activities	(25,174)	(19,945)
Cash flows from investing activities:
Capital expenditures	(422)	(2,187)
Net cash used in investing activities	(422)	(2,187)
Cash flows from financing activities:
Proceeds from exercise of stock options		14
Proceeds from borrowings under Revolving Credit Agreement		7,565
Repayments under Revolving Credit Agreement		(4,211)
Repayments under mortgage agreement and capital leases	(110)	(253)
Cash payments for taxes related to net share settlements of equity compensation and awards	(474)
Net cash (used in) provided by financing activities	(584)	3,115
Effect of exchange rate changes on cash and cash equivalents	(37)	46
Decrease in cash and cash equivalents and restricted cash	(26,217)	(18,971)
Cash and cash equivalents and restricted cash - beginning of period	83,373	22,603
Cash and cash equivalents and restricted cash - end of period	57,156	3,632
Cash and cash equivalents	57,156	2,632
Restricted cash		1,000
Total cash and cash equivalents and restricted cash	$ 57,156	$ 3,632

Basis of Presentation

Basis of Presentation	9 Months Ended
Basis of Presentation	Apr. 30, 2024
Basis of Presentation [Abstract]
Basis of Presentation	Note 1 – Basis of Presentation Enzo Biochem, Inc. (the “Company,” “we,” “our” or “Enzo”), is a manufacturer and supplier of a comprehensive portfolio of thousands of high-quality products, including antibodies, genomic probes, assays, biochemicals, and proteins. The Company’s proprietary products and technologies play central roles in translational research and drug development areas, including cell biology, genomics, assays, immunohistochemistry, and small molecule chemistry. Enzo Biochem, Inc.’s Life Science division supports the work of research centers and industry partners. Enzo Biochem, Inc. has a broad and deep intellectual property portfolio, with patent coverage across many vital enabling technologies. The accompanying consolidated financial statements include the accounts of Enzo Biochem, Inc. and its wholly-owned subsidiaries, Enzo Life Sciences, Inc. (“Enzo Life Sciences”), Enzo Therapeutics, Inc. (“Enzo Therapeutics”), Enzo Realty LLC (“Enzo Realty”), and Enzo Realty II LLC (“Enzo Realty II”), collectively or with one or more of its subsidiaries referred to as the “Company” or “Companies.” The financial statements also include as discontinued operations the accounts of its wholly owned subsidiary Enzo Clinical Labs, Inc. (“Enzo Clinical Labs”). Effective July 24, 2023 we completed the sale of certain assets used in its clinical services operations to Laboratory Corporation of America Holdings, a Delaware corporation (“Labcorp”), and thereby exited the clinical services business. See Note 2. The Company has one reportable segment, Products. The consolidated balance sheet as of April 30, 2024, the consolidated statements of operations, comprehensive loss and stockholders’ equity for the three and nine months ended April 30, 2024 and 2023, and the consolidated statements of cash flows for the nine months ended April 30, 2024 and 2023 (the “interim statements”) are unaudited. In the opinion of management, all adjustments (which include normal recurring adjustments) necessary to present fairly the financial position and operating results for the interim periods have been made. Certain information and footnote disclosure, normally included in annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”), have been condensed or omitted. The interim statements should be read in conjunction with the consolidated financial statements for the fiscal year ended July 31, 2023 and notes thereto contained in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission. The consolidated balance sheet at July 31, 2023 has been derived from the audited financial statements at that date. The results of operations for the nine months ended April 30, 2024 are not necessarily indicative of the results that may be expected for the fiscal year ending July 31, 2024. Principles of consolidation The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and include the accounts of the Company and its wholly-owned subsidiaries, Enzo Life Sciences (and its wholly-owned foreign subsidiaries), Enzo Therapeutics, Enzo Realty, Enzo Realty II, and Enzo Clinical Labs (a corporate entity with discontinued operations). All intercompany transactions and balances have been eliminated. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. Contingencies Contingencies are evaluated and a liability is recorded when the matter is both probable and reasonably estimable. Gain contingencies are evaluated and not recognized until the gain is realizable or realized. Fair Value Measurements The Company determines fair value measurements used in its consolidated financial statements based upon the exit price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants exclusive of any transaction costs, as determined by either the principal market or the most advantageous market. Inputs used in the valuation techniques to derive fair values are classified based on a three-level hierarchy. The basis for fair value measurements for each level within the hierarchy is described below with Level 1 having the highest priority and Level 3 having the lowest. Level 1 Quoted prices in active markets for identical assets or liabilities. Level 2 Quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which all significant inputs are observable in active markets. Level 3 Valuations derived from valuation techniques in which one or more significant inputs are unobservable. Cash and cash equivalents Cash and cash equivalents consist of demand deposits with banks and highly liquid money market funds. At April 30, 2024 and July 31, 2023, the Company had cash and cash equivalents in foreign bank accounts of $1,240 and $419, respectively. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash and cash equivalents and accounts receivable. The Company believes the fair value of the aforementioned financial instruments approximates the cost due to the immediate or short-term nature of these items. At April 30, 2024 and July 31, 2023, the Company had cash deposited in certain financial institutions in excess of federally insured levels. The Company regularly monitors the financial stability of these financial institutions and believes that it is not exposed to any significant credit risk in cash and cash equivalents or restricted cash. Concentration of credit risk with respect to the Company’s Products segment is mitigated by the diversity of the Company’s customers and their dispersion across many different geographic regions. To reduce risk, the Company routinely assesses the financial strength of these customers and, consequently, believes that its accounts receivable credit exposure with respect to these customers is limited. Income Taxes The Company accounts for income taxes under the liability method of accounting for income taxes. Under the liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. The liability method requires that any tax benefits recognized for net operating loss carry forwards and other items be reduced by a valuation allowance when it is more likely than not that the benefits may not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under the liability method, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Effect of New Accounting Pronouncements - Recently Adopted Accounting Pronouncements In June 2016, the Financial Accounting Standards Board (FASB) issued ASU No. 2016-13 Financial Instruments – Credit Losses In November 2023, FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures We reviewed all other recently issued accounting pronouncements and have concluded they are not applicable or not expected to be significant to the accounting for our operations.

Discontinued Operations

Discontinued Operations	9 Months Ended
Discontinued Operations	Apr. 30, 2024
Discontinued Operations [Abstract]
Discontinued operations	Note 2 – Discontinued operations Prior to July 24, 2023, we operated a clinical laboratory, doing business as Enzo Clinical Labs, which provided reference, molecular and esoteric diagnostic medical testing services in the New York, New Jersey, and Connecticut medical communities. Effective July 24, 2023, we completed the sale of certain assets used in the operation of Enzo Clinical Labs and the assignment of certain clinical lab liabilities to Labcorp for an aggregate purchase price of $113.25 million in cash, subject to customary closing adjustments. In connection with the sale, $5 million of escrowed proceeds were included in prepaid and other assets as of April 30, 2024 and in other assets as of July 31, 2023. Excluded from the sale of the clinical services assets were its cash and accounts receivable. In accordance with the sale, we ceased our clinical services operations but continue winding down activities. As a consequence of the sale, for the three and nine months ended April 30, 2024 and 2023 we have classified as discontinued operations all income and expenses attributable to the clinical services business. The following table sets forth the condensed operating results of the discontinued operations for the three and nine months ended April 30: Three Months Ended Nine Months Ended 2024 2023 2024 2023 Net revenues $ — $ 8,622 $ — $ 28,619 Cost of revenues — 9,993 — 30,538 Selling, general and administrative 835 5,810 3,085 18,207 Research and development — 91 — 694 Legal and related expenses — 21 — 192 Other (income) expense, net 444 (3 ) 1,333 (12 ) Income tax (benefit) (390 ) — (390 ) — Loss from discontinued operations $ (889 ) $ (7,290 ) $ (4,028 ) $ (21,000 ) Other expense, net for the nine months ended April 30, 2024 is primarily the cost for a third party to maintain and destroy health records according to statute related to the discontinued operations. The following table sets forth the condensed carrying amounts of major classes of assets and liabilities of the discontinued operations as of the dates indicated: April 30, July 31, Carrying amounts of major current assets included as part of discontinued operations: Trade receivables $ 97 $ 1,675 Prepaid and other current 313 54 Total current assets 410 1,729 Carrying amounts of major current liabilities included as part of discontinued operations: Trade payables and accrued liabilities 8,709 20,616 Operating lease liabilities and other 1,985 2,215 Total current liabilities 10,694 22,831 Current liabilities of discontinued operations, net 10,284 21,102 Carrying amount of major non-current assets included as part of discontinued operations: Right of use assets $ 5,658 $ 7,001 Other 78 62 Total non-current assets 5,736 7,063 Carrying amount of major non-current liabilities included as part of discontinued operations: Operating lease liabilities and other 4,191 6,096 Non-current assets of discontinued operations, net $ 1,545 $ 967 During the nine months ended April 30, 2024, the cash used in operating and investing activities of the discontinued operations was $14,219 and $0, respectively, primarily for reductions of trade payables and accrued liabilities, partially offset by collections of accounts receivable, and the period loss. During the nine months ended April 30, 2023, the cash used in operating activities and investing activities of the discontinued operations was $12,564 and $447, respectively.

Net Income (Loss) Per Share

Net Income (Loss) Per Share	9 Months Ended
Net Income (Loss) Per Share	Apr. 30, 2024
Net Income (Loss) Per Share [Abstract]
Net income (loss) per share	Note 3 – Net income (loss) per share Basic net income (loss) per share represents net income (loss) divided by the weighted average number of common shares outstanding during the period. The dilutive effect of potential common shares, consisting of outstanding stock options, and unvested restricted stock units and performance stock units, is determined using the treasury stock method. As a result of the net loss for the three and nine months ended April 30, 2024 and 2023, diluted weighted average shares outstanding are the same as basic weighted average shares outstanding, and do not include the potential common shares from stock options, restricted stock units, warrants, assumed conversion of debentures, or unearned performance stock units because to do so would be anti-dilutive. For the three and nine months ended April 30, 2024, the effect of approximately 1,832,000 and 2,542,000, respectively, of outstanding “out of the money” options to purchase common shares and the effect of approximately 77,000 and 133,000, respectively, of outstanding restricted stock units were excluded from the calculation of diluted net (loss) income per share because their effect would be anti-dilutive. During the three and nine months ended April 30, 2024, the effect of approximately 848,000 and 688,000, respectively, of shares related to warrants and the effect of approximately 1,688,000 and 1,438,000, respectively of shares related to the assumed conversion of debentures were excluded from the calculation of diluted weighted average shares outstanding because their effect would be anti-dilutive. For the three and nine months ended April 30, 2023, approximately 173,000 and 105,000, respectively, of potential common shares from “in the money options” and unvested restricted stock and performance stock units were excluded from the calculation of diluted (loss) per share because their effect would be antidilutive. For the three and nine months ended April 30, 2023, the effect of approximately 4,097,000 and 3,627,000, respectively, of outstanding “out of the money” options to purchase common shares were excluded from the calculation of diluted net (loss) income per share because their effect would be anti-dilutive.

Revenue Recognition

Revenue Recognition	9 Months Ended
Revenue Recognition	Apr. 30, 2024
Revenue Recognition [Abstract]
Revenue Recognition	Note 4 – Revenue Recognition Products Revenue The Company generates revenue from the sale of our single-use products used in the identification of genomic information. Revenue is recorded net of sales tax. The Company considers revenue to be earned when all of the following criteria are met: the Company has a contract with a customer that creates enforceable rights and obligations; promised products are identified; the transaction price is determinable; and the Company has transferred control of the promised items to the customer. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer, and is the unit of account in the contract. The transaction price for the contract is measured as the amount of consideration the Company expects to receive in exchange for the goods expected to be transferred. A contract’s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, control of the distinct good or service is transferred. Transfer of control for the Company’s products is generally at shipment or delivery, depending on contractual terms, but occurs when title and risk of loss transfers to the customer which represents the point in time when the customer obtains the use of and substantially all of the remaining benefit of the product. As such, the Company’s performance obligation related to product sales is satisfied at a point in time. The Company recognizes a receivable when it has an unconditional right to payment, which represents the amount the Company expects to collect in a transaction and is most often equal to the transaction price in the contract. Payment terms for shipments to end-user and distributor customers may range from 30 to 90 days. Amounts billed to customers for shipping and handling are included in revenue, while the related shipping and handling costs are reflected in cost of revenues. Products revenue by geography is as follows: Three Months Ended Nine Months Ended 2024 2023 2024 2023 United States $ 4,793 $ 5,043 $ 14,594 $ 13,282 Europe 2,359 1,688 6,783 5,869 Asia Pacific 870 754 3,004 2,951 Products revenue $ 8,022 $ 7,485 $ 24,381 $ 22,102 As of August 1, 2023 and 2022, accounts receivable from continuing operations was $4,808 and $4,762, respectively.

Supplemental Disclosure for Sta

Supplemental Disclosure for Statement of Cash Flows	9 Months Ended
Supplemental Disclosure for Statement of Cash Flows	Apr. 30, 2024
Supplemental Disclosure for Statement of Cash Flows [Abstract]
Supplemental disclosure for statement of cash flows	Note 5 – Supplemental disclosure for statement of cash flows During the nine months ended April 30, 2024 and 2023, interest paid by the Company was $275 and $204, respectively. For the nine months ended April 30, 2024 and 2023, the net reductions in the measurement of right of use assets and liabilities included in cash flows from operating activities was $306 and $5, respectively. The changes are included in changes in accrued liabilities, other current liabilities, and other liabilities in the statement of cash flows. In connection with the completed sale of certain assets used in the operation of Enzo Clinical Labs, $5,000 of escrowed proceeds were included in prepaid and other assets as of April 30, 2024 and in other assets as of July 31, 2023. In connection with the full payment of a mortgage in July 2023, the restricted cash collateral deposit of $1,000 was released during the nine months ended April 30, 2024. During the nine months ended April 30, 2024, state taxes paid on the gain on the completed sale of certain assets used in the operation of Enzo Clinical Labs were $729. For the nine months ended April 30, 2024 and 2023, tax on capital paid by the Company was $23 and $9, respectively. During the nine months ended April 30, 2024, the Company disbursed $474 for taxes related to net share settlement of bonuses paid in stock to a current senior executive and a former senior executive, and for taxes related to a net share settlement of a performance stock unit.

Inventories

Inventories	9 Months Ended
Inventories	Apr. 30, 2024
Inventories [Abstract]
Inventories	Note 6 – Inventories Inventories, net consisted of the following as at: April 30, July 31, Raw materials $ 2,067 $ 2,206 Work in process 2,708 2,599 Finished products 2,549 3,134 $ 7,324 $ 7,939

Convertible Debentures and Othe

Convertible Debentures and Other Current Debt	9 Months Ended
Convertible Debentures and Other Current Debt	Apr. 30, 2024
Convertible Debentures and Other Current Debt [Abstract]
Convertible debentures and other current debt	Note 7 – Convertible debentures and other current debt On May 19, 2023, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with each of the purchasers that are parties thereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”) and JGB Collateral, LLC, a Delaware limited liability company, as collateral agent for the Purchasers (the “Agent”). Pursuant to the Purchase Agreement, the Company agreed to sell to the Purchasers (i) 10% Original Issue Discount Secured Convertible Debentures (the “Debentures”) with an aggregate principal amount of $7,608 and (ii) warrants to purchase up to 1,000,000 shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”), for an exercise price of $2.31 per share, the average of the three (3) daily volume weighted average prices of the Common Stock as defined in the Purchase Agreement (“VWAP”) prior to the closing date (the “Warrants”), subject to adjustments as set forth in the Warrants, for a total purchase price of $7,000. The Purchase Agreement contains customary representations, warranties and covenants. The transactions contemplated by the Purchase Agreement were consummated on May 19, 2023. Pursuant to ASC 825, Fair Value Option Debentures The Debentures bear interest at a rate of 10% per annum (which interest rate is increased to 18% per annum five days after the occurrence and continuance of an Event of Default (as defined in the Debentures)), have a maturity date of May 20, 2024 and are convertible, at any time after their issuance date at the option of the Purchasers, into shares of Common Stock at a conversion price equal to $3.01 per share (the “Conversion Price”), subject to adjustment as set forth in the Debentures. Following the July 24, 2023 consummation of the Company’s sale of certain assets and assignment of certain liabilities of Enzo Clinical Labs to Labcorp pursuant to the Asset Purchase Agreement, dated March 16, 2023, the Company prepaid $4,000 of the outstanding principal amount prior to July 31, 2023. The Company’s obligations under the Debentures may be accelerated, at the Purchasers’ election, upon the occurrence of certain customary events of default. As of April 30, 2024 and July 31, 2023, there were no events of default. The Debentures contain customary representations, warranties and covenants including among other things and subject to certain exceptions, covenants that restrict the Company from incurring additional indebtedness, creating or permitting liens on assets, amending its charter documents and bylaws, repurchasing or otherwise acquiring more than a de minimis number of its Common Stock or equivalents thereof, repaying outstanding indebtedness, paying dividends or distributions, assigning or selling certain assets, making or holding any investments, and entering into transactions with affiliates. The following table presents a reconciliation of the beginning and ending balances of the Debentures measured at fair value on a recurring basis that use significant unobservable inputs (Level 3) and the related change in fair value expense recorded in the consolidated statement of operations during the nine months ended April 30, 2024: Fair value, July 31, 2023 $ 2,514 Change in fair value of convertible debentures 1,095 Fair value, April 30, 2024 $ 3,609 During the three months ended April 30, 2024, the change in fair value expense recorded was $384. As of April 30, 2024, the outstanding principal of the Debentures was $3,609, which was paid in full, plus interest of $20, on May 20, 2024, the date the Debentures matured. Security Agreement and Subsidiary Guarantees In connection with the Purchase Agreement, on May 19, 2023, the Company, certain of the Company’s domestic subsidiaries (“Guarantors”), the Purchasers and the Agent entered into a Security Agreement (the “Security Agreement”), pursuant to which the Company and the Guarantors granted, for the benefit of the Purchasers, to secure the Company’s obligations under the Purchase Agreement and the Debentures. Subsequent to the payoff of the Debentures on May 20, 2024, all obligations under the Security Agreement were terminated. Warrants The Warrants are exercisable for five years from May 19, 2023, at an exercise price of $2.31 per share, which is the average of three (3) daily VWAPs prior to the closing date, subject, with certain exceptions, to adjustments in the event of stock splits, dividends, subsequent dilutive offerings and certain fundamental transactions, as more fully described in the Warrant. Registration Rights Agreement In connection with the Purchase Agreement, on May 19, 2023, the Company and the Purchasers entered into a Registration Rights Agreement, pursuant to which the Company is obligated to register the shares of Company Common Stock issuable upon exercise of the Debentures and the Warrants. The Company has registered the shares. With the full payoff of the Debentures, there is no longer a right to a conversion of the Debentures into shares.

Long Term Debt

Long Term Debt	9 Months Ended
Long Term Debt	Apr. 30, 2024
Long Term Debt [Abstract]
Long term debt	Note 8 – Long term debt In April 2020, the Company’s subsidiary in Switzerland received a loan of CHF 400 (or $400, based on the foreign exchange rate as of July 31, 2020) from the Swiss government under the “Corona Krise” emergency loan program in response to the COVID-19 pandemic. This loan is uncollateralized and bears 0% interest. In January 2022, the bank agent of the Swiss government informed our subsidiary that the loan had to be fully amortized within a maximum of eight years and that the first of semiannual amortization payments of CHF 33 would begin in March 2022. In March 2022, the subsidiary made its first semi-annual principal repayment of CHF 33 (or $35 based on exchange rates). Based on this amortization schedule, the loan will be repaid by September 2027. The current portion of this loan is included in other current liabilities and the long term portion in long term debt – net as of April 30, 2024 and July 31, 2023. Minimum future annual principal payments under this agreement as of April 30, 2024 are as follows: July 31, Total 2024 $ — 2025 73 2026 73 2027 73 2028 36 Total principal payments 255 Less: current portion (75 ) Long term debt – net $ 180

Leases

Leases	9 Months Ended
Leases	Apr. 30, 2024
Leases [Abstract]
Leases	Note 9 – Leases The Company determines if an arrangement is or contains a lease at contract inception. The Company leases buildings, office space, and equipment through operating leases. Generally, a right-of-use asset, representing the right to use the underlying asset during the lease term, and a lease liability, representing the payment obligation arising from the lease, are recognized on the balance sheet at lease commencement based on the present value of the payment obligation. For operating leases, expense is recognized on a straight-line basis over the lease term. Short-term leases with an initial term of 12 months or less are not recorded on the balance sheet; the Company recognizes lease expense for these leases on a straight-line basis over the lease term. The Company primarily uses its incremental borrowing rate in determining the present value of lease payments as the Company’s leases generally do not provide an implicit rate. The Company has lease agreements with (i) right-of-use asset payments and (ii) non-lease components (e.g. payments related to maintenance fees, utilities, etc.) which have generally been combined and accounted for as a single lease component. The Company’s leases have remaining terms of less than 1 year to 4 years, some of which include options to extend the leases for up to 3 years. The Company’s lease terms may include renewal options that are reasonably certain to be exercised and termination options that are reasonably certain not to be exercised. Certain of the Company’s lease agreements include rental payments adjusted periodically for inflation or a market rate which are included in the lease liabilities. Leases Balance Sheet Classification April 30, July 31, Assets Operating Right-of-use assets $ 2,959 $ 3,626 Total lease assets $ 2,959 $ 3,626 Liabilities Current: Operating Current portion of operating lease liabilities $ 799 $ 980 Non-current: Operating Operating lease liabilities, non-current 2,595 3,160 Total lease liabilities $ 3,394 $ 4,140 Components of lease cost were as follows: Three months ended Nine months ended 2024 2023 2024 2023 Operating lease cost – net (a) $ 141 $ 108 $ 422 $ 472 (a) Net of $126 and $378 of sublease income for the three and nine months ended April 30, 2024, respectively, and $126 and $252 for the three and nine months ended April 30, 2023, respectively. The maturities of the Company’s lease liabilities as of April 30, 2024 are as follows: Maturity of lease liabilities, years ending July 31, Operating 2024 $ 278 2025 896 2026 886 2027 881 2028 808 Total lease payments 3,749 Less: Interest (a) (355 ) Present value of lease liabilities $ 3,394 (a) Primarily calculated using the Company’s incremental borrowing rate. Lease term and discount rate for the nine months ended April 30 were as follows: Lease term and discount rate 2024 2023 Weighted-average remaining lease term (years) - operating leases 4.1 years 5.1 years Weighted-average discount rate – operating leases 5.1 % 5.1 % See Note 5 for cash flow information on cash paid for amounts included in the measurement of lease liabilities for the nine months ended April 30, 2024 and 2023.

Accrued Liabilities and Other C

Accrued Liabilities and Other Current Liabilities	9 Months Ended
Accrued Liabilities and Other Current Liabilities	Apr. 30, 2024
Accrued Liabilities and Other Current Liabilities [Abstract]
Accrued Liabilities and other current liabilities	Note 10 – Accrued Liabilities and other current liabilities Accrued liabilities consist of: April 30, July 31, Payroll, benefits and commissions $ 3,053 $ 7,421 Professional fees 451 610 Legal 1,282 2,248 Other 590 1,464 $ 5,376 $ 11,743 Self-Insured Medical Plan The Company self-funds medical insurance coverage for certain of its U.S. based employees. The risk to the Company is believed to be limited through the use of individual and aggregate stop loss insurance. As of April 30, 2024 and July 31, 2023, the Company had established reserves of $99 and $631, respectively, which are included in accrued liabilities for payroll, benefits and commissions, for claims that have been reported but not paid and for claims that have been incurred but not reported. The reserve is based upon the Company’s historical payment trends, claim history and current estimates.

Stockholders_ Equity

Stockholders’ Equity	9 Months Ended
Stockholders’ Equity	Apr. 30, 2024
Stockholders’ Equity [Abstract]
Stockholders’ equity	Note 11 – Stockholders’ equity Controlled Equity Offering In May 2023, the Company entered into a sales agreement (the “Sales Agreement”) with B. Riley Securities, Inc. as sales agent (“Riley”). Under the Sales Agreement, the Company may offer and sell, from time to time, through Riley, shares of the Company’s common stock, par value $0.01 per share (“Shares”) having an aggregate offering price of up to $30 million. The Company pays Riley a commission of 3.0% of the aggregate gross proceeds received under the Sale Agreement. The Company is not obligated to make any sales of Shares under the Sales Agreement. The offering of Shares pursuant to the Sales Agreement will terminate upon the earlier of (a) the sale of all of the Shares subject to the Sales Agreement or (b) the termination of the Sales Agreement by Riley or the Company, as permitted therein. In May 2023, the Company filed with the SEC a “shelf” registration and sales agreement prospectus covering the Sales Agreement. A total of $150 million of securities, including those covered by the Sales Agreement, may be sold under the shelf registration which was declared effective in July 2023. During the fourth quarter of the fiscal year ended July 31, 2023, the Company sold 276,479 shares for net proceeds of $386. There was no activity during the nine months ended April 30, 2024. Incentive stock plans In January 2011, the Company’s stockholders approved the adoption of the 2011 Incentive Plan (the “2011 Plan”) for the issuance of equity awards, including, among others, options, restricted stock, restricted stock units and performance stock units for up to 3,000,000 shares of common stock. In January 2018, the Company’s stockholders approved the amendment and restatement of the 2011 Plan (the “Amended and Restated 2011 Plan”) to increase the number of shares of common stock available for grant under the 2011 Plan by 2,000,000 shares of common stock bringing the total number of shares available for grant to 5,000,000 shares of common stock. On October 7, 2020, the Company’s Board of Directors approved the amendment and restatement of the Amended and Restated 2011 Plan, with an effective date of October 7, 2020 and subject to approval by the Company’s stockholders at the 2020 annual meeting of stockholders of the Company. The amendment and restatement of the Amended and Restated 2011 Plan was for purposes of, among other things, (i) increasing the shares of common stock available for grant under the Amended and Restated 2011 Plan by an additional 4,000,000 shares of common stock bringing the total number of shares available for grant to 9,000,000 shares of common stock and (ii) extending the term of the Amended and Restated 2011 Plan until October 7, 2030. In January 2021, the Company’s stockholders approved the amendment and restatement of the Amended and Restated 2011 Plan. The exercise price of options granted under the Amended and Restated 2011 Plan, as amended and restated, is equal to or greater than fair market value of the common stock on the date of grant. The Amended and Restated 2011 Plan, as amended and restated, will terminate at the earliest of (a) such time as no shares of common stock remain available for issuance under the plan, (b) termination of the plan by the Company’s Board of Directors, or (c) October 7, 2030. Awards outstanding upon expiration of the Amended and Restated 2011 Plan, as amended and restated, will remain in effect until they have been exercised or terminated, or have expired. As of April 30, 2024, there were approximately 5,006,000 shares of common stock available for grant under the Amended and Restated 2011 Plan, as amended and restated. The Company estimates the fair value of each stock option award on the measurement date using a Black-Scholes option pricing model or the fair value of our stock at the date of grant. The fair value of awards is amortized to expense on a straight-line basis over the requisite service period. The Company expenses restricted stock awards based on vesting requirements, primarily time elapsed. Performance stock awards are not recognized until it is probable they will be earned. At such time, their expense is then recognized over the requisite service period, including that portion of the service period already elapsed. Options granted pursuant to the plans may be either incentive stock options or non-statutory options. The 2011 Plan provides for the issuance of stock options, restricted stock and restricted stock unit awards which generally vest over a two or three year period. During the nine months ended April 30, 2024, the Company recognized $519 of share based compensation with respect to stock options and $367 of share based compensation with respect to restricted stock units as a result of the termination of the former CEO during the period then ended. See Note 14. The amounts of share-based compensation expense recognized in the periods presented are as follows: Three months ended Nine months ended 2024 2023 2024 2023 Stock options and performance stock units $ 90 $ 211 $ 833 $ 622 Restricted stock units 117 277 710 666 $ 207 $ 488 $ 1,543 $ 1,288 The following table sets forth the amount of expense related to share-based payment arrangements included in specific line items in the accompanying statements of operations: Three months ended Nine months ended 2024 2023 2024 2023 Selling, general and administrative $ 199 $ 482 $ 1,518 $ 1,271 Cost of revenues 8 6 25 17 $ 207 $ 488 $ 1,543 $ 1,288 No excess tax benefits were recognized during the nine month periods ended April 30, 2024 and 2023. The following table summarizes stock option activity during the nine month period ended April 30, 2024: Options Weighted Weighted Aggregate Outstanding at July 31, 2023 3,829,500 $ 2.61 — Granted 125,000 1.38 Exercised — — $ Cancelled or expired (2,122,630 ) $ 1.61 Outstanding at end of period 1,831,870 $ 2.37 2.1 years $ — Exercisable at end of period 1,215,203 $ 2.49 1.8 years $ — As of April 30, 2024, the total future compensation cost related to non-vested options, not yet recognized in the statements of operations, was $491 and the weighted average period over which the remaining expense of these awards is expected to be recognized is approximately one and one half years. The intrinsic value of stock option awards represents the value of the Company’s closing stock price on the last trading day of the period in excess of the exercise price multiplied by the number of options that are outstanding. Restricted Stock Units The following table summarizes RSU activity for the nine months ended April 30, 2024: Number of Weighted Weighted Aggregate Outstanding at beginning of fiscal year 557,490 $ 2.21 1.1 years 825 Granted 405,825 $ 1.31 — Vested (475,222 ) $ 2.24 Cancelled (100,000 ) $ 1.97 Outstanding at end of period 388,093 $ 1.31 1.5 years $ 404 Expected to vest at end of period 388,093 $ 1.31 1.5 years $ 404 Certain directors had not received their vested RSU shares, totaling 144,530, as of July 31, 2023. These shares were issued during the nine months ended April 30, 2024. During the nine months ended April 30, 2024, 173,333 RSUs vested and 100,000 were cancelled as a result of the termination of the former CEO. The vested shares had not been issued as of April 30, 2024, but were subsequently issued in May 2024. During the three and nine months ended April 30, 2024, the Company recognized shared based compensation expense for RSU’s of $117 and $710, respectively. As of April 30, 2024, the total future compensation cost related to non-vested RSUs, not yet recognized in the statements of operations, was $390 and the weighted average period over which the remaining expense of these awards is expected to be recognized is approximately one and a half years. Performance Stock Units During the three and nine months ended April 30, 2024, the Company recognized no

Segment Reporting

Segment Reporting	9 Months Ended
Segment Reporting	Apr. 30, 2024
Segment Reporting [Abstract]
Segment reporting	Note 12 – Segment reporting The Company has one reportable segment, Products, which develops, manufactures, and markets products to research and pharmaceutical customers. The Company evaluates segment performance based on segment income (loss) before taxes. Costs excluded from segment income (loss) before taxes and reported as “Corporate & Other” consist of corporate general and administrative costs which are not allocable to the Products segment. Legal and related expenses incurred to defend the Company’s intellectual property, which may result in settlements recognized in another segment and other general corporate matters are considered a component of the Corporate & Other segment. Legal and related expenses specific to the Products’ segment’s activities are allocated to that segment. Management of the Company assesses assets on a consolidated basis only and therefore, assets by reportable segment have not been included in the reportable segments below. The accounting policies of the reportable segment are the same as those described in the summary of significant accounting policies. The following financial information represents the operating results of the reportable segments of the Company: Three months ended April 30, 2024 Products Corporate Consolidated Revenues $ 8,022 $ — $ 8,022 Operating costs and expenses: Cost of revenues 4,289 — 4,289 Research and development 595 10 605 Selling, general and administrative 2,881 1,598 4,479 Legal and related expenses — 692 692 Total operating costs and expenses 7,765 2,300 10,065 Operating income (loss) 257 (2,300 ) (2,043 ) Other income (expense) Interest 37 689 726 Change in fair value of convertible debentures — (384 ) (384 ) Other (31 ) 125 94 Foreign exchange loss (524 ) — (524 ) Loss before taxes $ (261 ) $ (1,870 ) $ (2,131 ) Depreciation and amortization included above $ 162 $ 175 $ 337 Share-based compensation included above: Selling, general and administrative 32 167 199 Cost of sales 8 — 8 Total $ 40 $ 167 $ 207 Capital expenditures $ 123 $ 20 $ 143 Three months ended April 30, 2023 Products Corporate Consolidated Revenues $ 7,485 $ — $ 7,485 Operating costs and expenses: Cost of revenues 4,476 — 4,476 Research and development 872 12 884 Selling, general and administrative 3,069 3,143 6,212 Legal and related expenses 19 4,246 4,265 Total operating costs and expenses 8,436 7,401 15,837 Operating loss (951 ) (7,401 ) (8,352 ) Other income (expense) Interest 30 (66 ) (36 ) Other 2 142 144 Foreign exchange gain 347 — 347 Loss before taxes $ (572 ) $ (7,325 ) $ (7,897 ) Depreciation and amortization included above $ 182 $ 93 $ 275 Share-based compensation included above: Selling, general and administrative 20 462 482 Cost of sales 6 — 6 Total $ 26 $ 462 $ 488 Capital expenditures $ 331 $ 282 $ 613 Nine months ended April 30, 2024 Products Corporate Consolidated Revenues $ 24,381 $ — $ 24,381 Operating costs and expenses: Cost of revenues 12,969 — 12,969 Research and development 2,012 23 2,035 Selling, general and administrative 9,266 7,284 16,550 Legal and related expenses 51 2,476 2,527 Total operating costs and expenses 24,298 9,783 34,081 Operating income (loss) 83 (9,783 ) (9,700 ) Other income (expense) Interest 104 2,491 2,595 Change in fair value of convertible debentures — (1,095 ) (1,095 ) Other (28 ) 401 373 Foreign exchange loss (842 ) — (842 ) Loss before taxes $ (683 ) $ (7,986 ) $ (8,669 ) Depreciation and amortization included above $ 500 $ 374 $ 874 Share-based compensation included above: Selling, general and administrative 97 1,421 1,518 Cost of sales 25 — 25 Total $ 122 $ 1,421 $ 1,543 Capital expenditures $ 369 $ 53 $ 422 Nine months ended April 30, 2023 Products Corporate Consolidated Revenues $ 22,102 $ — $ 22,102 Operating costs and expenses: Cost of revenues 13,681 — 13,681 Research and development 2,675 33 2,708 Selling, general and administrative 8,989 8,089 17,078 Legal and related expenses 55 6,105 6,160 Total operating costs and expenses 25,400 14,227 39,627 Operating loss (3,298 ) (14,227 ) (17,525 ) Other income (expense) Interest 84 15 99 Other 6 256 262 Foreign exchange gain 1,022 — 1,022 Income (loss) before taxes $ (2,186 ) $ (13,956 ) $ (16,142 ) Depreciation and amortization included above $ 518 $ 267 $ 785 Share-based compensation included above: Selling, general and administrative 60 1,211 1,271 Cost of sales 17 — 17 Total $ 77 $ 1,211 $ 1,288 Capital expenditures $ 1,268 $ 506 $ 1,774

Contingencies

Contingencies	9 Months Ended
Contingencies	Apr. 30, 2024
Contingencies [Abstract]
Contingencies	Note 13 – Contingencies Ransomware Attack In April 2023, the Company experienced a ransomware attack (the “ransomware attack”) that impacted certain critical information technology systems. In response, we promptly deployed containment measures, including disconnecting our systems from the internet, launching an investigation with assistance from third-party cybersecurity experts, and notifying law enforcement. We adhered to our disaster recovery plan, which enabled us to maintain operations throughout the incident response process. We are in the process of evaluating the full scope of the costs and related impacts of this incident. The Company’s facilities remained open, and we continued to provide services to patients and partners. We later became aware that certain data, including names, test information, and Social Security numbers, was accessed, and in some instances, exfiltrated from the Company’s information technology systems as part of this incident. The investigation identified unauthorized access to or acquisition of clinical test information of approximately 2,470,000 individuals. The Social Security numbers of approximately 600,000 of these individuals may also have been involved. Additionally, the Company has determined that some employees’ information may have been involved. The Company has provided notice to the individuals whose information may have been involved, as well as to regulatory authorities, in accordance with applicable law. Enzo Biochem is currently subject to regulatory inquiry from the New York Attorney General, a joint inquiry from the Connecticut and New Jersey Attorneys General and an inquiry from the Utah Attorney General. All inquiries ask questions about the ransomware attack, as well as the corrective actions taken in response. We are unable to evaluate the likelihood of an outcome, favorable or unfavorable, to the Company or to estimate the amount or range of any potential liability, if any, at this time. Enzo Biochem is also subject to regulatory inquiries from the U.S. Department of Health and Human Services Office for Civil Rights (the “Office for Civil Rights”) regarding the ransomware attack. It is not known at this time whether the Office for Civil Rights will seek a penalty against the Company. We are unable to evaluate the likelihood of an outcome, favorable or unfavorable, to the Company or to estimate the amount or range of any potential liability, if any, at this time. There is also pending Class Action litigation: In re Enzo Biochem Data Breach Litigation In the Eastern District of New York twenty putative class actions have been consolidated alleging various harms stemming from the April 2023 data incident. Interim lead counsel has been appointed and filed a Consolidated Amended Complaint on November 13, 2023. The complaint seeks to certify a federal class as well as several state subclasses. The Consolidated Amended Complaint brings various statutory and common law claims including negligence, negligence per se, breach of fiduciary duty, breach of implied contract, breach of the implied covenant of good faith and fair dealing, violation of the New York’s General Business Law § 349, Invasion of Privacy, violations of the Connecticut Unfair Trade Practices Act, and violations of the New Jersey Consumer Fraud Act. The Company filed its motion to dismiss on April 8, 2024. Plaintiffs filed their Opposition on May 23, 2024 and our Reply was filed on May 30, 2024. We are now awaiting the court’s decision. Maria Sgambati et al., v. Enzo Biochem, Inc., et al This is a putative class action pending in state court alleging various harms stemming from the April 2023 data incident. The complaint seeks to certify a class of New York residents. The complaint brings claims of negligence; negligence per se Louis v. Enzo Biochem, Inc. et al. This is a putative class action pending in state court alleging various harms stemming from the April 2023 data incident. The complaint seeks to certify a class of New York citizens. The complaint brings claims of negligence; negligence per se A provision was made in the financial statements as of July 31, 2023 for the above matters based on a reasonable estimate of loss; however, the actual exposure may differ. Patent Matters The Company (as plaintiff) has brought cases in the United States District Court for the District of Delaware (“the Court”), alleging patent infringement against various companies. At this time, the majority of such cases have been resolved. There is currently one case that was originally brought by the Company that is still pending in the Court. In that case, Enzo alleges patent infringement of the ’197 patent against Becton Dickinson defendants. The claims in that case are stayed. On September 2, 2021, the U.S. Patent and Trademark Office (“PTO”) issued a non-final office action in an ex parte ex parte ex parte Arbitration with former executives The Company terminated the employment of Elazar Rabbani, Ph.D., the Company’s former Chief Executive Officer, effective April 21, 2022. Dr. Rabbani was a board director of the Company until the Annual Meeting on January 31, 2024, when his term expired. Dr. Rabbani was a party to an employment agreement with the Company that entitled him to certain termination benefits, including severance pay, acceleration of vesting of share-based compensation, and continuation of benefits. Based on the terms of his employment agreement, the Company estimated and accrued a charge of $2,600 in fiscal year 2022. The charge was partially offset by the reversal of bonus accruals. In May 2022, the Company paid Dr. Rabbani $2,123 in severance (the payment constituted taxable income but the Company did not withhold taxes from the payment). In July 2022, the Company paid Dr. Rabbani’s income and other withholding taxes of $1,024 related to that payment on Dr. Rabbani’s behalf. Dr. Rabbani disputed, among other things, the Company’s decision to not award him a bonus for fiscal year 2021 and the amount of severance that was owed to him under his employment agreement. On July 8, 2022, the Company filed a demand for arbitration with the American Arbitration Association (the “AAA”) seeking, among other things, a declaration that the Company has fully satisfied its contractual obligations to Dr. Rabbani and seeking the tax withholding reimbursement referenced above. On August 4, 2022, Dr. Rabbani filed counterclaims in the arbitration seeking, among other things, a bonus for fiscal year 2021 and additional severance that he asserted was owed to him. At the parties’ joint request, the arbitration has been stayed while the parties work towards resolving the matter. A provision was made in the financial statements as of July 31, 2023 based on a reasonable estimate of loss; however, the actual exposure may differ. On February 25, 2022, Barry Weiner, the Company’s co-founder and President, notified the Company that he was terminating his employment as President of the Company for “Good Reason” as defined in his employment agreement. The Company accepted Mr. Weiner’s termination, effective April 19, 2022, but disagreed with Mr. Weiner’s assertion regarding “Good Reason.” On October 24, 2023, the Company and Mr. Weiner reached an agreement resolving the dispute and a provision was made in the financial statements as of July 31, 2023 based on the settlement agreement. The Company paid Mr. Weiner $3,600, less applicable withholding taxes, related to the agreement in November 2023. Other Matters On or about March 2, 2023, a verified complaint was filed in the Supreme Court of the State of New York, New York County captioned Elazar Rabbani (as plaintiff) v. Mary Tagliaferri, et al. (as defendants), Index No. 651120/2023. The verified complaint purports to assert causes of action for breach of fiduciary duty and corporate waste under N.Y.B.C.L. § 720, and seeks an accounting and certain injunctive relief. Plaintiff served a copy of the verified complaint on Enzo’s agent for service in New York on or about March 13, 2023. On August 4, 2023, defendants moved to dismiss all the causes of action asserted in the verified complaint. Plaintiff filed an amended complaint on or about October 4, 2023, adding, among other things, an additional cause of action for violation of N.Y.B.C.L. § 626. On October 23, 2023, Defendants filed a reply in further support of their motion to dismiss. On October 24, 2023, Plaintiff sought leave to file an opposition brief. Defendants filed an opposition to that request on October 26, 2023. On October 31, 2023, in response to a question from the Court’s law clerk, Defendants reiterated that they had elected to apply their original motion to dismiss to the amended pleading. On November 6, 2023, Plaintiff filed an opposition to Defendants’ motion to dismiss. On November 17, 2023, Defendants filed a reply brief in further support of their motion to dismiss the Amended Complaint. The Company cannot predict the outcome of this matter. Oral argument on Defendants’ motion to dismiss is scheduled for June 18, 2024. On or about September 26, 2023, James G. Wolf, Individually and as the Trustee of the Wolf Family Charitable Foundation, Barbaranne R. Wolf, Stephen Paul Wolf, and Preston M. Wolf initiated an appraisal action against Enzo Biochem, Inc. in the New York Supreme Court for Suffolk County. Petitioners seek an appraisal of the value of their shares in the Company. The amount of damages sought by the Petitioners is unspecified. The Company will defend itself vigorously in the appraisal action. In our discontinued Clinical Labs operations, third-party payers, including government programs, may decide to deny payment or recoup payments for testing that they contend was improperly billed or not medically necessary, against their coverage determinations, or for which they believe they have otherwise overpaid (including as a result of their own error), and we may be required to refund payments that we received. In April 2024, the Company engaged in settlement negotiations for a government payer and reached a verbal settlement. A provision is included in the financial statements based on a reasonable estimate of loss; however, the actual exposure may differ.

Departure and Appointment of Ce

Departure and Appointment of Certain Officers	9 Months Ended
Departure and Appointment of Certain Officers	Apr. 30, 2024
Departure and Appointment of Certain Officers [Abstract]
Departure and Appointment of Certain Officers	Note 14 – Departure and Appointment of Certain Officers On September 5, 2023, the Company entered into a Separation Agreement and General Release (the “Separation Agreement”) with Hamid Erfanian, the Company’s Chief Executive Officer, which provides for Mr. Erfanian’s separation of employment, resignations from his positions as Chief Executive Officer and as a director of the Company and the payment of severance benefits as described below. Pursuant to the Separation Agreement, Mr. Erfanian’s resignations as Chief Executive Officer and as a director became effective immediately and his final date of employment with the Company was November 18, 2023 (the “Separation Date”). Pursuant to the Separation Agreement, Mr. Erfanian is entitled to the following severance benefits: (i) a payment equaling twelve (12) months of his annual base salary of $624, subject to standard payroll deductions and withholdings; (ii) a lump-sum payment of $187, representing his annual bonus; (iii) a grant of restricted shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”), in an amount equal to $1,502 with 50% of the restricted Common Stock granted as soon as reasonably practicable after September 13, 2023, and the remaining 50% granted on the earlier of July 24, 2024 or a Change in Control of the Company (as defined in Mr. Erfanian’s employment agreement with the Company); and (iv) the immediate vesting on the Separation Date of the remainder of a restricted stock unit award of 260,000 shares of Common Stock and an option to purchase 700,000 shares of Common Stock that were previously granted to Mr. Erfanian upon his employment. The foregoing are subject to continued compliance with existing restrictive covenants under Mr. Erfanian’s employment agreement with the Company and his reaffirmation. The severance benefits with respect to salary and bonus were accrued during the three months ended October 31, 2023. The share-based charges related to the immediate vesting of the remainder of the restricted stock unit award and options granted upon employment were also recognized during the three months ended October 31, 2023. On September 5, 2023, the Company’s board of directors appointed Kara Cannon, the Company’s Chief Operating Officer, to serve as Interim Chief Executive Officer of the Company, which became effective immediately upon Mr. Erfanian’s resignation as Chief Executive Officer. On January 31, 2024, the Company’s board of directors appointed Kara Cannon as the Company’s Chief Executive Officer and Patricia Eckert, CPA as the Company’s Chief Financial Officer.

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
Pay vs Performance Disclosure - USD ($) $ in Thousands	Apr. 30, 2024	Apr. 30, 2023	Apr. 30, 2024	Apr. 30, 2023
Pay vs Performance Disclosure
Net Income (Loss)	$ (3,020)	$ (15,187)	$ (12,697)	$ (37,142)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Apr. 30, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	9 Months Ended
Accounting Policies, by Policy (Policies)	Apr. 30, 2024
Accounting Policies [Abstract]
Principles of consolidation	Principles of consolidation The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and include the accounts of the Company and its wholly-owned subsidiaries, Enzo Life Sciences (and its wholly-owned foreign subsidiaries), Enzo Therapeutics, Enzo Realty, Enzo Realty II, and Enzo Clinical Labs (a corporate entity with discontinued operations). All intercompany transactions and balances have been eliminated.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.
Contingencies	Contingencies Contingencies are evaluated and a liability is recorded when the matter is both probable and reasonably estimable. Gain contingencies are evaluated and not recognized until the gain is realizable or realized.
Fair Value Measurements	Fair Value Measurements The Company determines fair value measurements used in its consolidated financial statements based upon the exit price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants exclusive of any transaction costs, as determined by either the principal market or the most advantageous market. Inputs used in the valuation techniques to derive fair values are classified based on a three-level hierarchy. The basis for fair value measurements for each level within the hierarchy is described below with Level 1 having the highest priority and Level 3 having the lowest. Level 1 Quoted prices in active markets for identical assets or liabilities. Level 2 Quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which all significant inputs are observable in active markets. Level 3 Valuations derived from valuation techniques in which one or more significant inputs are unobservable.
Cash and cash equivalents	Cash and cash equivalents Cash and cash equivalents consist of demand deposits with banks and highly liquid money market funds. At April 30, 2024 and July 31, 2023, the Company had cash and cash equivalents in foreign bank accounts of $1,240 and $419, respectively.
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash and cash equivalents and accounts receivable. The Company believes the fair value of the aforementioned financial instruments approximates the cost due to the immediate or short-term nature of these items. At April 30, 2024 and July 31, 2023, the Company had cash deposited in certain financial institutions in excess of federally insured levels. The Company regularly monitors the financial stability of these financial institutions and believes that it is not exposed to any significant credit risk in cash and cash equivalents or restricted cash. Concentration of credit risk with respect to the Company’s Products segment is mitigated by the diversity of the Company’s customers and their dispersion across many different geographic regions. To reduce risk, the Company routinely assesses the financial strength of these customers and, consequently, believes that its accounts receivable credit exposure with respect to these customers is limited.
Income Taxes	Income Taxes The Company accounts for income taxes under the liability method of accounting for income taxes. Under the liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. The liability method requires that any tax benefits recognized for net operating loss carry forwards and other items be reduced by a valuation allowance when it is more likely than not that the benefits may not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under the liability method, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.
Effect of New Accounting Pronouncements - Recently Adopted Accounting Pronouncements	Effect of New Accounting Pronouncements - Recently Adopted Accounting Pronouncements In June 2016, the Financial Accounting Standards Board (FASB) issued ASU No. 2016-13 Financial Instruments – Credit Losses In November 2023, FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures We reviewed all other recently issued accounting pronouncements and have concluded they are not applicable or not expected to be significant to the accounting for our operations.

Discontinued Operations (Tables

Discontinued Operations (Tables)	9 Months Ended
Discontinued Operations (Tables)	Apr. 30, 2024
Discontinued Operations [Abstract]
Schedule of Condensed Operating Results of the Discontinued Operations	The following table sets forth the condensed operating results of the discontinued operations for the three and nine months ended April 30: Three Months Ended Nine Months Ended 2024 2023 2024 2023 Net revenues $ — $ 8,622 $ — $ 28,619 Cost of revenues — 9,993 — 30,538 Selling, general and administrative 835 5,810 3,085 18,207 Research and development — 91 — 694 Legal and related expenses — 21 — 192 Other (income) expense, net 444 (3 ) 1,333 (12 ) Income tax (benefit) (390 ) — (390 ) — Loss from discontinued operations $ (889 ) $ (7,290 ) $ (4,028 ) $ (21,000 )
Schedule of Major Classes of Assets and liabilities of the Discontinued Operations	The following table sets forth the condensed carrying amounts of major classes of assets and liabilities of the discontinued operations as of the dates indicated: April 30, July 31, Carrying amounts of major current assets included as part of discontinued operations: Trade receivables $ 97 $ 1,675 Prepaid and other current 313 54 Total current assets 410 1,729 Carrying amounts of major current liabilities included as part of discontinued operations: Trade payables and accrued liabilities 8,709 20,616 Operating lease liabilities and other 1,985 2,215 Total current liabilities 10,694 22,831 Current liabilities of discontinued operations, net 10,284 21,102 Carrying amount of major non-current assets included as part of discontinued operations: Right of use assets $ 5,658 $ 7,001 Other 78 62 Total non-current assets 5,736 7,063 Carrying amount of major non-current liabilities included as part of discontinued operations: Operating lease liabilities and other 4,191 6,096 Non-current assets of discontinued operations, net $ 1,545 $ 967

Revenue Recognition (Tables)

Revenue Recognition (Tables)	9 Months Ended
Revenue Recognition (Tables)	Apr. 30, 2024
Revenue Recognition [Abstract]
Schedule of Products Revenue by Geography	Products revenue by geography is as follows: Three Months Ended Nine Months Ended 2024 2023 2024 2023 United States $ 4,793 $ 5,043 $ 14,594 $ 13,282 Europe 2,359 1,688 6,783 5,869 Asia Pacific 870 754 3,004 2,951 Products revenue $ 8,022 $ 7,485 $ 24,381 $ 22,102

Inventories (Tables)

Inventories (Tables)	9 Months Ended
Inventories (Tables)	Apr. 30, 2024
Inventories [Abstract]
Schedule of Inventories, Net	Inventories, net consisted of the following as at: April 30, July 31, Raw materials $ 2,067 $ 2,206 Work in process 2,708 2,599 Finished products 2,549 3,134 $ 7,324 $ 7,939

Convertible Debentures and Ot_2

Convertible Debentures and Other Current Debt (Tables)	9 Months Ended
Convertible Debentures and Other Current Debt (Tables)	Apr. 30, 2024
Convertible Debentures and Other Current Debt [Abstract]
Schedule of Debentures Measured at Fair Value on a Recurring Basis	The following table presents a reconciliation of the beginning and ending balances of the Debentures measured at fair value on a recurring basis that use significant unobservable inputs (Level 3) and the related change in fair value expense recorded in the consolidated statement of operations during the nine months ended April 30, 2024: Fair value, July 31, 2023 $ 2,514 Change in fair value of convertible debentures 1,095 Fair value, April 30, 2024 $ 3,609

Long Term Debt (Tables)

Long Term Debt (Tables)	9 Months Ended
Long Term Debt (Tables)	Apr. 30, 2024
Long Term Debt [Abstract]
Schedule of Minimum Future Annual Principal Payments	Minimum future annual principal payments under this agreement as of April 30, 2024 are as follows: July 31, Total 2024 $ — 2025 73 2026 73 2027 73 2028 36 Total principal payments 255 Less: current portion (75 ) Long term debt – net $ 180

Leases (Tables)

Leases (Tables)	9 Months Ended
Leases (Tables)	Apr. 30, 2024
Leases [Abstract]
Schedule of lease	Certain of the Company’s lease agreements include rental payments adjusted periodically for inflation or a market rate which are included in the lease liabilities. Leases Balance Sheet Classification April 30, July 31, Assets Operating Right-of-use assets $ 2,959 $ 3,626 Total lease assets $ 2,959 $ 3,626 Liabilities Current: Operating Current portion of operating lease liabilities $ 799 $ 980 Non-current: Operating Operating lease liabilities, non-current 2,595 3,160 Total lease liabilities $ 3,394 $ 4,140 Three months ended Nine months ended 2024 2023 2024 2023 Operating lease cost – net (a) $ 141 $ 108 $ 422 $ 472 (a) Net of $126 and $378 of sublease income for the three and nine months ended April 30, 2024, respectively, and $126 and $252 for the three and nine months ended April 30, 2023, respectively. Lease term and discount rate 2024 2023 Weighted-average remaining lease term (years) - operating leases 4.1 years 5.1 years Weighted-average discount rate – operating leases 5.1 % 5.1 %
Schedule of Maturities of the Company’s Lease Liabilities	The maturities of the Company’s lease liabilities as of April 30, 2024 are as follows: Maturity of lease liabilities, years ending July 31, Operating 2024 $ 278 2025 896 2026 886 2027 881 2028 808 Total lease payments 3,749 Less: Interest (a) (355 ) Present value of lease liabilities $ 3,394 (a) Primarily calculated using the Company’s incremental borrowing rate.

Accrued Liabilities and Other_2

Accrued Liabilities and Other Current Liabilities (Tables)	9 Months Ended
Accrued Liabilities and Other Current Liabilities (Tables)	Apr. 30, 2024
Accrued Liabilities and Other Current Liabilities [Abstract]
Schedule of Accrued Liabilities	Accrued liabilities consist of: April 30, July 31, Payroll, benefits and commissions $ 3,053 $ 7,421 Professional fees 451 610 Legal 1,282 2,248 Other 590 1,464 $ 5,376 $ 11,743

Stockholders_ Equity (Tables)

Stockholders’ Equity (Tables)	9 Months Ended
Stockholders’ Equity (Tables)	Apr. 30, 2024
Stockholders’ Equity [Abstract]
Schedule of Share-based Compensation Expense	The amounts of share-based compensation expense recognized in the periods presented are as follows: Three months ended Nine months ended 2024 2023 2024 2023 Stock options and performance stock units $ 90 $ 211 $ 833 $ 622 Restricted stock units 117 277 710 666 $ 207 $ 488 $ 1,543 $ 1,288 Three months ended Nine months ended 2024 2023 2024 2023 Selling, general and administrative $ 199 $ 482 $ 1,518 $ 1,271 Cost of revenues 8 6 25 17 $ 207 $ 488 $ 1,543 $ 1,288
Schedule of Stock Option Activity	The following table summarizes stock option activity during the nine month period ended April 30, 2024: Options Weighted Weighted Aggregate Outstanding at July 31, 2023 3,829,500 $ 2.61 — Granted 125,000 1.38 Exercised — — $ Cancelled or expired (2,122,630 ) $ 1.61 Outstanding at end of period 1,831,870 $ 2.37 2.1 years $ — Exercisable at end of period 1,215,203 $ 2.49 1.8 years $ —
Schedule of Restricted Stock Unit (“RSU”) Activity	The following table summarizes RSU activity for the nine months ended April 30, 2024: Number of Weighted Weighted Aggregate Outstanding at beginning of fiscal year 557,490 $ 2.21 1.1 years 825 Granted 405,825 $ 1.31 — Vested (475,222 ) $ 2.24 Cancelled (100,000 ) $ 1.97 Outstanding at end of period 388,093 $ 1.31 1.5 years $ 404 Expected to vest at end of period 388,093 $ 1.31 1.5 years $ 404

Segment Reporting (Tables)

Segment Reporting (Tables)	9 Months Ended
Segment Reporting (Tables)	Apr. 30, 2024
Segment Reporting [Abstract]
Schedule of Financial Information Represents the Operating Results of the Reportable Segments	The following financial information represents the operating results of the reportable segments of the Company: Products Corporate Consolidated Revenues $ 8,022 $ — $ 8,022 Operating costs and expenses: Cost of revenues 4,289 — 4,289 Research and development 595 10 605 Selling, general and administrative 2,881 1,598 4,479 Legal and related expenses — 692 692 Total operating costs and expenses 7,765 2,300 10,065 Operating income (loss) 257 (2,300 ) (2,043 ) Other income (expense) Interest 37 689 726 Change in fair value of convertible debentures — (384 ) (384 ) Other (31 ) 125 94 Foreign exchange loss (524 ) — (524 ) Loss before taxes $ (261 ) $ (1,870 ) $ (2,131 ) Depreciation and amortization included above $ 162 $ 175 $ 337 Share-based compensation included above: Selling, general and administrative 32 167 199 Cost of sales 8 — 8 Total $ 40 $ 167 $ 207 Capital expenditures $ 123 $ 20 $ 143 Products Corporate Consolidated Revenues $ 7,485 $ — $ 7,485 Operating costs and expenses: Cost of revenues 4,476 — 4,476 Research and development 872 12 884 Selling, general and administrative 3,069 3,143 6,212 Legal and related expenses 19 4,246 4,265 Total operating costs and expenses 8,436 7,401 15,837 Operating loss (951 ) (7,401 ) (8,352 ) Other income (expense) Interest 30 (66 ) (36 ) Other 2 142 144 Foreign exchange gain 347 — 347 Loss before taxes $ (572 ) $ (7,325 ) $ (7,897 ) Depreciation and amortization included above $ 182 $ 93 $ 275 Share-based compensation included above: Selling, general and administrative 20 462 482 Cost of sales 6 — 6 Total $ 26 $ 462 $ 488 Capital expenditures $ 331 $ 282 $ 613 Products Corporate Consolidated Revenues $ 24,381 $ — $ 24,381 Operating costs and expenses: Cost of revenues 12,969 — 12,969 Research and development 2,012 23 2,035 Selling, general and administrative 9,266 7,284 16,550 Legal and related expenses 51 2,476 2,527 Total operating costs and expenses 24,298 9,783 34,081 Operating income (loss) 83 (9,783 ) (9,700 ) Other income (expense) Interest 104 2,491 2,595 Change in fair value of convertible debentures — (1,095 ) (1,095 ) Other (28 ) 401 373 Foreign exchange loss (842 ) — (842 ) Loss before taxes $ (683 ) $ (7,986 ) $ (8,669 ) Depreciation and amortization included above $ 500 $ 374 $ 874 Share-based compensation included above: Selling, general and administrative 97 1,421 1,518 Cost of sales 25 — 25 Total $ 122 $ 1,421 $ 1,543 Capital expenditures $ 369 $ 53 $ 422 Products Corporate Consolidated Revenues $ 22,102 $ — $ 22,102 Operating costs and expenses: Cost of revenues 13,681 — 13,681 Research and development 2,675 33 2,708 Selling, general and administrative 8,989 8,089 17,078 Legal and related expenses 55 6,105 6,160 Total operating costs and expenses 25,400 14,227 39,627 Operating loss (3,298 ) (14,227 ) (17,525 ) Other income (expense) Interest 84 15 99 Other 6 256 262 Foreign exchange gain 1,022 — 1,022 Income (loss) before taxes $ (2,186 ) $ (13,956 ) $ (16,142 ) Depreciation and amortization included above $ 518 $ 267 $ 785 Share-based compensation included above: Selling, general and administrative 60 1,211 1,271 Cost of sales 17 — 17 Total $ 77 $ 1,211 $ 1,288 Capital expenditures $ 1,268 $ 506 $ 1,774

Basis of Presentation (Details)

Basis of Presentation (Details) - USD ($) $ in Thousands	Apr. 30, 2024	Jul. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash and cash equivalents in foreign bank	$ 1,240	$ 419

Discontinued Operations (Detail

Discontinued Operations (Details) - USD ($) $ in Thousands	1 Months Ended	9 Months Ended
Discontinued Operations (Details) - USD ($) $ in Thousands	Jul. 24, 2023	Apr. 30, 2024	Apr. 30, 2023
Discontinued Operations [Abstract]
Aggregate purchase price	$ 113,250
Prepaid and other assets		$ 5,000
Cash used in operation activities		14,219	$ 12,564
Cash used in investing activities		$ 0	$ 447

Discontinued Operations (Deta_2

Discontinued Operations (Details) - Schedule of Condensed Operating Results of the Discontinued Operations - Parent [Member] - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Apr. 30, 2024	Apr. 30, 2023	Apr. 30, 2024	Apr. 30, 2023
Schedule of Condensed Operating Results of the Discontinued Operations [Line Items]
Net revenues		$ 8,622		$ 28,619
Cost of revenues		9,993		30,538
Selling, general and administrative	835	5,810	3,085	18,207
Research and development		91		694
Legal and related expenses		21		192
Other (income) expense, net	444	(3)	1,333	(12)
Income tax (benefit)	(390)		(390)
Loss from discontinued operations	$ (889)	$ (7,290)	$ (4,028)	$ (21,000)

Discontinued Operations (Deta_3

Discontinued Operations (Details) - Schedule of Major Classes of Assets and liabilities of the Discontinued Operations - Parent Company [Member] - USD ($) $ in Thousands	Apr. 30, 2024	Jul. 31, 2023
Carrying amounts of major current assets included as part of discontinued operations:
Trade receivables	$ 97	$ 1,675
Prepaid and other current	313	54
Total current assets	410	1,729
Carrying amounts of major current liabilities included as part of discontinued operations:
Trade payables and accrued liabilities	8,709	20,616
Operating lease liabilities and other	1,985	2,215
Total current liabilities	10,694	22,831
Current liabilities of discontinued operations, net	10,284	21,102
Carrying amount of major non-current assets included as part of discontinued operations:
Right of use assets	5,658	7,001
Other	78	62
Total non-current assets	5,736	7,063
Carrying amount of major non-current liabilities included as part of discontinued operations:
Operating lease liabilities and other	4,191	6,096
Non-current assets of discontinued operations, net	$ 1,545	$ 967

Net Income (Loss) Per Share (De

Net Income (Loss) Per Share (Details) - shares		3 Months Ended	9 Months Ended
Net Income (Loss) Per Share (Details) - shares	Apr. 30, 2023	Apr. 30, 2024	Apr. 30, 2024	Apr. 30, 2023
Net Income (Loss) Per Share [Line Items]
Common shares outstanding	4,097,000	1,832,000	2,542,000	3,627,000
Restricted Stock Units [Member]
Net Income (Loss) Per Share [Line Items]
Common shares outstanding		77,000	133,000
Debenture [Member]
Net Income (Loss) Per Share [Line Items]
Common shares outstanding		1,688,000	1,438,000
Unvested Restricted Stock and Performance Stock Units [Member]
Net Income (Loss) Per Share [Line Items]
Common shares outstanding	173,000			105,000
Warrant [Member]
Net Income (Loss) Per Share [Line Items]
Common shares outstanding		848,000	688,000

Revenue Recognition (Details)

Revenue Recognition (Details) - USD ($) $ in Thousands	Apr. 30, 2024	Aug. 01, 2023	Jul. 31, 2023	Aug. 01, 2022
Revenue Recognition [Abstract]
Accounts receivable from continuing operations	$ 3,935	$ 4,808	$ 4,808	$ 4,762

Revenue Recognition (Details) -

Revenue Recognition (Details) - Schedule of Products Revenue by Geography - Products revenue [Member] - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Apr. 30, 2024	Apr. 30, 2023	Apr. 30, 2024	Apr. 30, 2023
Schedule of Products Revenue by Geography [Line Items]
Products revenue	$ 8,022	$ 7,485	$ 24,381	$ 22,102
United States [Member]
Schedule of Products Revenue by Geography [Line Items]
Products revenue	4,793	5,043	14,594	13,282
Europe [Member]
Schedule of Products Revenue by Geography [Line Items]
Products revenue	2,359	1,688	6,783	5,869
Asia Pacific [Member]
Schedule of Products Revenue by Geography [Line Items]
Products revenue	$ 870	$ 754	$ 3,004	$ 2,951

Supplemental Disclosure for S_2

Supplemental Disclosure for Statement of Cash Flows (Details) - USD ($) $ in Thousands	9 Months Ended
	Apr. 30, 2024	Apr. 30, 2023	Jul. 31, 2023
Supplemental Disclosure for Statement of Cash Flows [Line Items]
Interest paid	$ 275	$ 204
Cash flows from operating activities	(25,174)	(19,945)
Escrowed proceeds			$ 5,000
Restricted cash	5,000		$ 1,000
Gain on sale of certain assets	729
Tax on capital	23	9
Tax on capital paid	474
Right of Use Assets and Liabilities [Member]
Supplemental Disclosure for Statement of Cash Flows [Line Items]
Cash flows from operating activities	306	$ 5
Prepaid and Other Assets [Member]
Supplemental Disclosure for Statement of Cash Flows [Line Items]
Escrowed proceeds	$ 5,000

Inventories (Details) - Schedul

Inventories (Details) - Schedule of Inventories, Net - USD ($) $ in Thousands	Apr. 30, 2024	Jul. 31, 2023
Schedule of Inventories, Net [Abstract]
Raw materials	$ 2,067	$ 2,206
Work in process	2,708	2,599
Finished products	2,549	3,134
Total inventories, net	$ 7,324	$ 7,939

Convertible Debentures and Ot_3

Convertible Debentures and Other Current Debt (Details) - USD ($) $ / shares in Units, $ in Thousands			3 Months Ended	9 Months Ended
	Jul. 31, 2023	May 19, 2023	Apr. 30, 2024	Apr. 30, 2024	Apr. 30, 2023	May 31, 2023
Convertible Debentures and Other Current Debt [Line Items]
Aggregate principal amount		$ 7,608
Warrants to purchase (in Shares)		1,000,000
Common stock, par value (in Dollars per share)	$ 0.01		$ 0.01	$ 0.01		$ 0.01
Warrants exercise price per share (in Dollars per share)		$ 2.31
Total purchase price		$ 7,000
Prepay outstanding principal amount	$ 4,000
Change in fair value convertible debentures				$ 1,095
Convertible debentures			$ 3,609	3,609
Warrants exercisable term		5 years
Warrant [Member]
Convertible Debentures and Other Current Debt [Line Items]
Common stock, par value (in Dollars per share)		$ 0.01
Warrants exercise price per share (in Dollars per share)		$ 2.31
Convertible Debentures [Member]
Convertible Debentures and Other Current Debt [Line Items]
Accrued interest				$ 20
Convertible Debentures [Member] \| JGB Collateral, LLC [Member]
Convertible Debentures and Other Current Debt [Line Items]
Original Issue Discount percentage		10%
Debentures [Member]
Convertible Debentures and Other Current Debt [Line Items]
Interest rate percentage			10%	10%
Increased interest rate				18%
Maturity date				May 20, 2024
Conversion Price [Member]
Convertible Debentures and Other Current Debt [Line Items]
Conversion price per share (in Dollars per share)			$ 3.01	$ 3.01
Change in fair value convertible debentures			$ 384

Convertible Debentures and Ot_4

Convertible Debentures and Other Current Debt (Details) - Schedule of Debentures Measured at Fair Value on a Recurring Basis - Level 3 [Member] $ in Thousands	9 Months Ended
	Apr. 30, 2024 USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair value, July 31, 2023	$ 2,514
Change in fair value of convertible debentures	1,095
Fair value, April 30, 2024	$ 3,609

Long Term Debt (Details)

Long Term Debt (Details) SFr in Thousands, $ in Thousands	1 Months Ended
Long Term Debt (Details) SFr in Thousands, $ in Thousands	Mar. 31, 2022 USD ($)	Mar. 31, 2022 CHF (SFr)	Jul. 31, 2020 USD ($)	Apr. 30, 2020 USD ($)
Long Term Debt [Line Items]
Foreign exchange rate amount \| $			$ 400	$ 400
Bearing interest rate				0%
Semiannual amortization payments (in Francs) \| SFr		SFr 33
Semi-annual principal repayment exchange rate.	$ 35	SFr 33

Long Term Debt (Details) - Sche

Long Term Debt (Details) - Schedule of Minimum Future Annual Principal Payments - USD ($) $ in Thousands	Apr. 30, 2024	Jul. 31, 2023
Long Term Debt [Abstract]
2024
2025	73
2026	73
2027	73
2028	36
Total principal payments	255
Less: current portion	(75)	$ (75)
Long term debt – net	$ 180	$ 269

Leases (Details)

Leases (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
Leases (Details) - USD ($) $ in Thousands	Apr. 30, 2024	Apr. 30, 2023	Apr. 30, 2024	Apr. 30, 2023
Leases (Details) [Line Items]
Lease term	3 years		3 years
Sublease income	$ 126	$ 126	$ 378	$ 252
Minimum [Member]
Leases (Details) [Line Items]
Lease term	1 year		1 year
Maximum [Member]
Leases (Details) [Line Items]
Lease term	4 years		4 years

Leases (Details) - Schedule of

Leases (Details) - Schedule of lease - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
		Apr. 30, 2024	Apr. 30, 2023	Apr. 30, 2024	Apr. 30, 2023	Jul. 31, 2023
Assets
Operating Right-of-use assets Balance Sheet Classification		Operating Right-of-use assets		Operating Right-of-use assets
Operating Right-of-use assets		$ 2,959		$ 2,959		$ 3,626
Total lease assets		$ 2,959		$ 2,959		3,626
Current:
Operating Current portion of operating lease liabilities Balance Sheet Classification		Operating Current portion of operating lease liabilities		Operating Current portion of operating lease liabilities
Operating Current portion of operating lease liabilities		$ 799		$ 799		980
Non-current:
Operating Operating lease liabilities, non-current Balance Sheet Classification		Operating Operating lease liabilities, non-current Balance Sheet Classification		Operating Operating lease liabilities, non-current Balance Sheet Classification
Operating Operating lease liabilities, non-current Balance Sheet Classification		$ 2,595		$ 2,595		3,160
Total lease liabilities		3,394		3,394		$ 4,140
Operating lease cost – net	[1]	$ 141	$ 108	$ 422	$ 472
Weighted-average remaining lease term (years) - operating leases		4 years 1 month 6 days	5 years 1 month 6 days	4 years 1 month 6 days	5 years 1 month 6 days
Weighted-average discount rate – operating leases		5.10%	5.10%	5.10%	5.10%

[1] Net of $126 and $378 of sublease income for the three and nine months ended April 30, 2024, respectively, and $126 and $252 for the three and nine months ended April 30, 2023, respectively.

Leases (Details) - Schedule o_2

Leases (Details) - Schedule of Maturities of the Company’s Lease Liabilities - USD ($) $ in Thousands		Apr. 30, 2024	Jul. 31, 2023
Schedule of Maturities of the Company’s Lease Liabilities [Abstract]
2024		$ 278
2025		896
2026		886
2027		881
2028		808
Total lease payments		3,749
Less: Interest	[1]	(355)
Present value of lease liabilities		$ 3,394	$ 4,140

[1] Primarily calculated using the Company’s incremental borrowing rate.

Accrued Liabilities and Other_3

Accrued Liabilities and Other Current Liabilities (Details) - USD ($) $ in Thousands	Apr. 30, 2024	Apr. 30, 2023
Payables and Accruals [Abstract]
Reserves amount	$ 99	$ 631

Accrued Liabilities and Other_4

Accrued Liabilities and Other Current Liabilities (Details) - Schedule of Accrued Liabilities - USD ($) $ in Thousands	Apr. 30, 2024	Jul. 31, 2023
Schedule of Accrued Liabilities [Abstract]
Payroll, benefits and commissions	$ 3,053	$ 7,421
Professional fees	451	610
Legal	1,282	2,248
Other	590	1,464
Accrued liabilities	$ 5,376	$ 11,743

Stockholders_ Equity (Details)

Stockholders’ Equity (Details) - USD ($) $ / shares in Units, $ in Thousands			3 Months Ended			9 Months Ended
	Jul. 31, 2023	Jan. 31, 2018	Apr. 30, 2024	Jul. 31, 2023	Apr. 30, 2023	Apr. 30, 2024	Apr. 30, 2023	May 31, 2023	Jan. 31, 2011
Stockholders’ Equity [Line Items]
Common stock, par value per share (in Dollars per share)	$ 0.01		$ 0.01	$ 0.01		$ 0.01		$ 0.01
Offering price								$ 30,000
Aggregate Gross Proceeds Percentage								3%
Sales agreement	$ 150,000
Common stock, shares issued (in Shares)				276,479
Net proceeds				$ 386
Shares of common stock (in Shares)						4,000,000
Common stock granted (in Shares)			5,006,000			5,006,000
Share based compensation expense			$ 207		$ 488	$ 1,543	$ 1,288
Total unrecognized compensation cost related to non-vested			491			$ 491
Vested shares (in Shares)	144,530					4,817
RSU vested shares (in Shares)						173,333
RSU cancelled shares (in Shares)						100,000
Share based compensation reversal			$ 7			$ 41
Restricted Stock Units (RSUs) [Member]
Stockholders’ Equity [Line Items]
Common stock granted (in Shares)			9,000,000			9,000,000
Share based compensation expense			$ 117			$ 710
Total unrecognized compensation cost related to non-vested			390			$ 390
RSU vested shares (in Shares)						475,222
RSU cancelled shares (in Shares)						100,000
Stock Option [Member]
Stockholders’ Equity [Line Items]
Share based compensation expense						$ 519
Performance Stock Units [Member]
Stockholders’ Equity [Line Items]
Share based compensation expense
Share Based Compensation [Member] \| Restricted Stock Units (RSUs) [Member]
Stockholders’ Equity [Line Items]
Share based compensation expense						$ 367
2011 Plan [Member]
Stockholders’ Equity [Line Items]
Stock units (in Shares)									3,000,000
Shares of common stock (in Shares)		2,000,000
Common stock granted (in Shares)		5,000,000

Stockholders_ Equity (Details)

Stockholders’ Equity (Details) - Schedule of Share-based Compensation Expense - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Apr. 30, 2024	Apr. 30, 2023	Apr. 30, 2024	Apr. 30, 2023
Schedule of Share-based Compensation Expense [Line Items]
Share-based compensation expense	$ 207	$ 488	$ 1,543	$ 1,288
Stock options and performance stock units [Member]
Schedule of Share-based Compensation Expense [Line Items]
Share-based compensation expense	90	211	833	622
Restricted stock units [Member]
Schedule of Share-based Compensation Expense [Line Items]
Share-based compensation expense	117	277	710	666
Selling, general and administrative [Member]
Schedule of Share-based Compensation Expense [Line Items]
Share-based compensation expense	199	482	1,518	1,271
Cost of revenues [Member]
Schedule of Share-based Compensation Expense [Line Items]
Share-based compensation expense	$ 8	$ 6	$ 25	$ 17

Stockholders_ Equity (Details_2

Stockholders’ Equity (Details) - Schedule of Stock Option Activity	9 Months Ended
	Apr. 30, 2024 USD ($) $ / shares shares
Schedule Of Stock Option Activity [Abstract]
Options, Outstanding, Beginning Balance \| shares	3,829,500
Weighted Average Exercise Price, Outstanding, Beginning Balance \| $ / shares	$ 2.61
Aggregate Intrinsic Value, Beginning Balance \| $
Options Granted \| shares	125,000
Weighted Average Exercise Price, Options Granted \| $ / shares	$ 1.38
Options Exercised \| shares
Weighted Average Exercise Price, Options Exercised \| $ / shares
Options Cancelled or Expired \| shares	(2,122,630)
Weighted Average Exercise Price, Cancelled or expired \| $ / shares	$ 1.61
Options, Outstanding, Ending Balance \| shares	1,831,870
Weighted Average Exercise Price, Options Forfeited \| $ / shares	$ 2.37
Weighted Average Remaining Contractual Term, Outstanding	2 years 1 month 6 days
Aggregate Intrinsic Value, Outstanding \| $
Options Exercisable at end of Period \| shares	1,215,203
Weighted Average Exercise Price, Outstanding, Ending Balance \| $ / shares	$ 2.49
Weighted Average Remaining Exercisable	1 year 9 months 18 days
Aggregate Intrinsic Value, Exercisable \| $

Stockholders_ Equity (Details_3

Stockholders’ Equity (Details) - Schedule of Restricted Stock Unit (“RSU”) Activity - Restricted Stock Units (RSUs) [Member] - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended	12 Months Ended
	Apr. 30, 2024	Jul. 31, 2023
Schedule of Restricted Stock Unit (“RSU”) Activity [Line Items]
Number of RSUs outstanding, Outstanding at ending of period	388,093	557,490
Weighted Average Fair Value per Unit at Date of Grant, Outstanding at ending of period	$ 1.31	$ 2.21
Weighted Average Remaining Contractual Term, Outstanding at ending of fiscal year	1 year 6 months	1 year 1 month 6 days
Aggregate Intrinsic Value, Outstanding at ending of period	$ 404	$ 825
Number of RSUs outstanding, Expected to vest at end of period	388,093
Weighted Average Fair Value per Unit at Date of Grant, Expected to vest at end of period	$ 1.31
Weighted Average Remaining Contractual Term, Expected to vest at end of period	1 year 6 months
Aggregate Intrinsic Value, Expected to vest at end of period	$ 404
Number of RSUs outstanding, Granted	405,825
Weighted Average Fair Value per Unit at Date of Grant, Granted	$ 1.31
Aggregate Intrinsic Value, Granted
Number of RSUs outstanding, Vested	(475,222)
Weighted Average Fair Value per Unit at Date of Grant, Vested	$ 2.24
Number of RSUs outstanding, Cancelled	(100,000)
Weighted Average Fair Value per Unit at Date of Grant, Cancelled	$ 1.97

Segment Reporting (Details)

Segment Reporting (Details)	9 Months Ended
Segment Reporting (Details)	Apr. 30, 2024
Segment Reporting [Abstract]
Reportable segment	1

Segment Reporting (Details) - S

Segment Reporting (Details) - Schedule of Financial Information Represents the Operating Results of the Reportable Segments - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Apr. 30, 2024	Apr. 30, 2023	Apr. 30, 2024	Apr. 30, 2023
Products [Member]
Segment Reporting Information [Line Items]
Revenues	$ 8,022	$ 7,485	$ 24,381	$ 22,102
Operating costs and expenses:
Cost of revenues	4,289	4,476	12,969	13,681
Research and development	595	872	2,012	2,675
Selling, general and administrative	2,881	3,069	9,266	8,989
Legal and related expenses		19	51	55
Total operating costs and expenses	7,765	8,436	24,298	25,400
Operating income (loss)	257	(951)	83	(3,298)
Other income (expense)
Interest	37	30	104	84
Change in fair value of convertible debentures
Other	(31)	2	(28)	6
Foreign exchange gain (loss)	(524)	347	(842)	1,022
Income (loss) before taxes	(261)	(572)	(683)	(2,186)
Depreciation and amortization included above	162	182	500	518
Share-based compensation included above:
Share-based compensation	40	26	122	77
Capital expenditures	123	331	369	1,268
Corporate & Other [Member]
Segment Reporting Information [Line Items]
Revenues
Operating costs and expenses:
Cost of revenues
Research and development	10	12	23	33
Selling, general and administrative	1,598	3,143	7,284	8,089
Legal and related expenses	692	4,246	2,476	6,105
Total operating costs and expenses	2,300	7,401	9,783	14,227
Operating income (loss)	(2,300)	(7,401)	(9,783)	(14,227)
Other income (expense)
Interest	689	(66)	2,491	15
Change in fair value of convertible debentures	(384)		(1,095)
Other	125	142	401	256
Foreign exchange gain (loss)
Income (loss) before taxes	(1,870)	(7,325)	(7,986)	(13,956)
Depreciation and amortization included above	175	93	374	267
Share-based compensation included above:
Share-based compensation	167	462	1,421	1,211
Capital expenditures	20	282	53	506
Consolidated [Member]
Segment Reporting Information [Line Items]
Revenues	8,022	7,485	24,381	22,102
Operating costs and expenses:
Cost of revenues	4,289	4,476	12,969	13,681
Research and development	605	884	2,035	2,708
Selling, general and administrative	4,479	6,212	16,550	17,078
Legal and related expenses	692	4,265	2,527	6,160
Total operating costs and expenses	10,065	15,837	34,081	39,627
Operating income (loss)	(2,043)	(8,352)	(9,700)	(17,525)
Other income (expense)
Interest	726	(36)	2,595	99
Change in fair value of convertible debentures	(384)		(1,095)
Other	94	144	373	262
Foreign exchange gain (loss)	(524)	347	(842)	1,022
Income (loss) before taxes	(2,131)	(7,897)	(8,669)	(16,142)
Depreciation and amortization included above	337	275	874	785
Share-based compensation included above:
Share-based compensation	207	488	1,543	1,288
Capital expenditures	143	613	422	1,774
Selling, General and Administrative Expenses [Member] \| Products [Member]
Share-based compensation included above:
Share-based compensation	32	20	97	60
Selling, General and Administrative Expenses [Member] \| Corporate & Other [Member]
Share-based compensation included above:
Share-based compensation	167	462	1,421	1,211
Selling, General and Administrative Expenses [Member] \| Consolidated [Member]
Share-based compensation included above:
Share-based compensation	199	482	1,518	1,271
Cost of Sales [Member] \| Products [Member]
Share-based compensation included above:
Share-based compensation	8	6	25	17
Cost of Sales [Member] \| Corporate & Other [Member]
Share-based compensation included above:
Share-based compensation
Cost of Sales [Member] \| Consolidated [Member]
Share-based compensation included above:
Share-based compensation	$ 8	$ 6	$ 25	$ 17

Contingencies (Details)

Contingencies (Details) - USD ($) $ in Thousands	1 Months Ended			9 Months Ended	12 Months Ended
Contingencies (Details) - USD ($) $ in Thousands	Nov. 30, 2023	Jul. 31, 2022	May 31, 2022	Apr. 30, 2023	Jun. 30, 2022
Contingencies [Line Items]
Acquisition shares (in Shares)				2,470,000
Number of security shares (in Shares)				600,000
Accrued expenses					$ 2,600
Payment of other income	$ 3,600	$ 1,024	$ 2,123

Departure and Appointment of _2

Departure and Appointment of Certain Officers (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	9 Months Ended
	Apr. 30, 2023	Apr. 30, 2024	Apr. 30, 2023	Jul. 31, 2023	May 31, 2023
Departure and Appointment of Certain Officers [Line Items]
Base salary		$ 624
Lump sum payment amount		$ 187
Par value (in Dollars per share)		$ 0.01		$ 0.01	$ 0.01
Restricted common stock granted percentage		50%
Remaining granted percentage		50%
Restricted Stock Units (RSUs) [Member]
Departure and Appointment of Certain Officers [Line Items]
NUmber of restricted stock unit (in Shares)		260,000
Common Stock [Member]
Departure and Appointment of Certain Officers [Line Items]
Par value (in Dollars per share)		$ 0.01
Restricted common stock		$ 1,502
NUmber of restricted stock unit (in Shares)	86,667		86,667
Common Stock [Member] \| Separation Agreement [Member]
Departure and Appointment of Certain Officers [Line Items]
Issuance of common stock (in Shares)		700,000